Truist Financial Corp Acquires 162 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Truist Financial Corp lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 519,564 shares of the medical research company’s stock after acquiring an additional 162 shares during the quarter. Truist Financial Corp owned approximately 0.29% of IQVIA worth $109,857,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in shares of IQVIA by 339.6% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock valued at $478,308,000 after buying an additional 1,597,003 shares during the period. Morningstar Investment Services LLC lifted its holdings in IQVIA by 96.9% in the fourth quarter. Morningstar Investment Services LLC now owns 1,231,916 shares of the medical research company’s stock worth $286,704,000 after buying an additional 606,333 shares during the period. Capital Research Global Investors boosted its position in IQVIA by 42.2% during the 4th quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company’s stock valued at $461,675,000 after acquiring an additional 592,372 shares in the last quarter. 1832 Asset Management L.P. grew its holdings in shares of IQVIA by 472.3% during the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after acquiring an additional 376,595 shares during the period. Finally, Renaissance Technologies LLC bought a new position in shares of IQVIA in the 2nd quarter worth approximately $70,610,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. The sale was disclosed in a document filed with the SEC, which is available through this link. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Stock Down 2.4 %

IQV stock opened at $231.37 on Wednesday. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The stock has a market capitalization of $42.18 billion, a P/E ratio of 31.61, a P/E/G ratio of 2.25 and a beta of 1.49. The business has a fifty day moving average price of $241.17 and a 200-day moving average price of $232.92.

IQVIA (NYSE:IQV) last posted its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. During the same quarter in the prior year, the business earned $2.22 EPS. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. Equities analysts forecast that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Evercore ISI upped their price target on IQVIA from $230.00 to $270.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 23rd. Truist Financial upped their target price on shares of IQVIA from $292.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. UBS Group lifted their price target on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. The Goldman Sachs Group began coverage on shares of IQVIA in a report on Thursday, June 6th. They issued a “buy” rating and a $270.00 price objective on the stock. Finally, StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Five analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $267.00.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.